Ariad Pharmaceuticals President and CEO Paris Panayiotopoulos, discusses patient response to cancer treatment Brigatinib. » Read More
CAMBRIDGE, Mass. _ Ariad Pharmaceuticals Inc. on Thursday reported second-quarter net income of $109.8 million, after reporting a loss in the same period a year earlier. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. This story was generated by Automated Insights using data from Zacks...
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports all the latest news in biotech. The Fast Money panel weighs in.
The "Halftime Report" traders give their top trades for the second half of the trading day.
The next takeout target in biotech? Here are three eligible candidates
Ariad Pharmaceuticals' CEO will retire this year in a settlement with hedge fund Sarissa Capital, capping months of agitation.
Corporate boards, meet the next Bill Ackmans and Carl Icahns of the world.
Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.
Some of the names on the move ahead of the open.
Sarissa Capital, which has a seat on Ariad Pharmaceuticals' board, is seeking to replace the company's CEO and may mount a proxy fight, a source said.
At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
Take a look at some of Tuesday's after-hours buzz: Apple, Cliffs & more
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Sapphire glass and biotech companies are bringing out the bears ahead of this week's earnings.
Industrials and material stocks were among the day's biggest gainers, while the technology sector ended lower, weighed down by big tech.
Take a look at some of Monday's midday movers:
Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.